Potent HCV Antiviral November 11, Activity by Inhibiting Fatty 2012 AASLD Acid Synthase George Kemble, PhD CSO
Slide 2: Drug Profile: Rationale & Approach
Drug Profile: Rationale & Approach • Unique mechanism of action to enable the following: – Pan genotype antiviral activity – Activity against other classes of drug resistant HCV mutants – Well tolerated – High barrier to resistance • Approach – Identify a cellular protein that is: • required for HCV
HCV Depends on the FASN Pathway FASN and/or its product interact with HCV at multiple points of the viral replication cycle Viral Entry RNA Replication Yang, et al, Hepatol. (2008) Virus Assembly and Exit Yu, et al, J. Virol (2006) Sakamoto, et al. Nat. Chem Biol (2005) Umehara, et al., Biochem & Bi
Slide 5: 3-V Inhibitors Are Potent & Specific
3-V Inhibitors Are Potent & Specific GT1b Replicon Infectious HCV (Gt2a) Inhibitory (50%) Concentration FASN FASN Enzyme GT1b GT2a Enzyme in vitro in cells Replicon* Virus* 50 nM 40 nM 60 nM 41 nM *No toxicity observed at highest concentration tested (10,000 nM) 5
FASN Inhibition Reduces HCV RNA In Passaged Cell Lines 100 (normalized to GAPHD) % HCV RNA Relative to 75 Untreated Cells 50 No Drug Prot. Inhib 3-V FASN Inhib 25 0 0 5 10 15 20 25 Days Post Treatment 7
Slide 8: Targeted Inhibition of FASN
Targeted Inhibition of FASN Palmitate add-back demonstrates on-target mechanism HCV FASN inhibitor Replicon HCV RNA replication (Luciferase) +/- Palmitate FASN enzymatic activity (palmitate synthesis) 1.5 de novo PMT(response) Response de novo palmitate 3-V inhib. TVB-0002722 3-V inhib. 3-V inhib. +
Slide 9: 3-V FASN inhibitors active against a range of HCV variants
3-V FASN inhibitors active against a range of HCV variants Median Effectiveness Concentration (µM) Active across genotypes Gt1a Gt1b Gt2 0.06 0.06 0.10 120 % Activity Compared 90 to WT replicon 3-V inhibitor 60 Control Cmpds 30 (DAAs) 0 Active against replicons resistant to other classes of HCV drug
Slide 10: FASN inhibited in rats following oral administration
FASN inhibited in rats following oral administration 150 * * % FASN Activity 125 Harvest Liver 100 Analyze 13C Palmitate 75 12 or 24 hours 50 25 3-V FASN inhibitor Add 13C Acetate Oral gavage 0 (t=0) Tracer Veh 30 60 Veh 30 60 (t=10 or 22 hrs) mpk mpk mpk mpk 12 hr 24 hr post dose post dose P<0.05 M
Slide 11: Profile of 3-V's FASN inhibitors
Profile of 3-V’s FASN inhibitors • Attractive compounds with unique mechanism of action – On-target activity confirmed – Potent (EC50’s < 100nM) – Pan genotype antiviral activity – Active against HCV mutants resistant to various classes of DAAs – Well tolerated following multiple day dosing at level
Slide 12: 3-V Biosciences, Inc. Contributors
3-V Biosciences, Inc. Contributors Doug Buckley Marc Evanchik Robert McDowell Stefan Moese Yamini Ohol Johan D. Oslob Visit Poster #1876 Merdad Parsey for additional information Amy K. Patick Mohan Sivaraja Sam Tep Satya Yendluri 12
Source: company website
More decks from Sagimet Biosciences Inc. - Series A